You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
中國生物製藥(01177.HK)"注射用硼替佐米"獲藥品補充申請批件
格隆匯 12-16 17:36

格隆匯12月16日丨中國生物製藥(01177.HK)公告,公司附屬公司南京正大天晴製藥有限公司的抗腫瘤藥"注射用硼替佐米"(商品名稱:益久)已獲中華人民共和國國家藥品監督管理局頒發藥品補充申請批件,增加若干藥品規格(包括增加1.0mg規格)。

硼替佐米是新型靶向抗癌藥,主要用於治療多發性骨髓瘤及被套細胞淋巴瘤。南京正大天晴製藥有限公司研製的注射用硼替佐米,於2018年九月獲批上市(當時獲批規格為3.5mg);此次獲批新增規格,可為患者提供更多的選擇,更好地滿足不同的市場需求。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account